Peer-reviewed veterinary case report
Blood test for hidden kidney disease in cats with hyperthyroidism
By Peterson, M E et al.·Published in Journal of veterinary internal medicine·2018·Animal Endocrine Clinic·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of Serum Symmetric Dimethylarginine Concentration as a Marker for Masked Chronic Kidney Disease in Cats With Hyperthyroidism.
- Species:
- cat
Plain-English summary
A group of hyperthyroid cats were tested for kidney disease using a blood marker called symmetric dimethylarginine (SDMA) before and after treatment. While none of the cats showed signs of kidney disease before treatment, 16% developed it within a few months after their hyperthyroidism was treated. Interestingly, some of these cats had high SDMA levels before treatment, suggesting that this test could help identify which hyperthyroid cats might later develop kidney problems. However, the SDMA test is not perfect, as it misses many cases of kidney disease in hyperthyroid cats.
People also search for: cat hyperthyroidism kidney disease · SDMA test for cats · signs of kidney disease in cats
Abstract
BACKGROUND: Hyperthyroidism can complicate (mask) the diagnosis of chronic kidney disease (CKD) because it increases glomerular filtration rate and decreases body muscle mass, both of which can lower serum creatinine concentrations. Currently, there is no clinical test that can reliably predict which hyperthyroid cats have concurrent azotemic CKD that will become apparent after treatment of the hyperthyroidism. OBJECTIVES: To investigate serum symmetric dimethylarginine (SDMA) concentration as a potential marker of masked azotemia in untreated hyperthyroid cats. ANIMALS: Two hundred and sixty-two hyperthyroid cats and 206 aged-matched, clinically normal cats. METHODS: Prospective study. We measured creatinine, urea nitrogen, SDMA, T, and TSH concentrations before and 1, 3, and 6 months after treatment with radioiodine (I) and classifiedI-treated cats as azotemic or nonazotemic based on persistent, post-treatment creatinine concentrations >2.1 mg/dL. Groups were compared via nonparametric tests, and diagnostic accuracy was determined by receiver operating characteristic analysis and logistic regression. RESULTS: No hyperthyroid cats were azotemic before treatment, but 42 (16%) became azotemic when rechecked at 4-8 months (median, 6 months) afterI treatment; of these, 14 had high SDMA concentrations before treatment. As a diagnostic test for pre-azotemic (masked) CKD in untreated hyperthyroid cats, SDMA showed a sensitivity of 33.3% and specificity of 97.7%. CONCLUSIONS AND CLINICAL IMPORTANCE: Finding a high serum SDMA concentration in a hyperthyroid cat can help predict development of azotemia after treatment. The test has high diagnostic test specificity (few false-positive results) but relatively low sensitivity (fails to predict azotemia in most hyperthyroid cats).
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/29377360/